Together, these actions: Increase insulin release only when blood glucose is elevated Reduce excess glucose production by the liver Slow stomach emptying, limiting post-meal glucose spikes Act on appetite centres in the brain, increasing fullness and reducing hunger Because insulin release is glucose-dependent, Mounjaro on its own has a low risk of causing hypoglycaemia (low blood sugar), unless combined with insulin or sulfonylurea medications
After that point, the peptide structure begins degrading, and you might notice reduced appetite suppression or slower weight loss even though you are taking the same dose
Other questions also warrant further research, such as understanding why some patients with OSA dont fully respond to GLP-1 treatments
Safety and Efficacy of GLP-1RAs in Weight Management
Our platform connects you with licensed providers who can review your surgical history and determine if tirzepatide is the right fit for you
Publisher | Google Scholor Wu J, Wang K, Wang X, Pang Y, Jiang C